UK markets closed
NIKKEI 225
38,837.46 -85.54 (-0.22%) HANG SENG
18,444.11 +41.11 (+0.22%) CRUDE OIL
72.85 -0.40 (-0.55%) GOLD FUTURES
2,347.30 -0.10 (-0.00%) DOW
38,711.29 +140.26 (+0.36%) Bitcoin GBP
55,346.14 +1,357.74 (+2.51%)
BMY Oct 2024 35.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:40AM EDT. Market open.
| Previous close | 0.6200 |
| Open | 0.6500 |
| Bid | 0.5800 |
| Ask | 0.6200 |
| Strike | 35.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.6300 - 0.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 4.05k |
ZacksBristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
Business WireBristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
PRINCETON, N.J., June 04, 2024--Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or....
Simply Wall St.Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested a year ago
The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do...
© 2024 Yahoo. All rights reserved.